Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 67

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 67
---
471 | ​ | ​ |
| Compensation Actually Paid                                                                                                                                                    | ​ | ​ | ​    | $ |  2,089,290 | ​ | ​ | ​ | ​    | $ | 4,116,164 | ​ | ​ | ​ | ​    | $ | 6,747,378 | ​ | ​ |

​

(3)

The non-PEO NEOs for each year reported are as follows:

​

•

For 2024: Aziz Sawaf and Brett Grimaud

​

•

For 2023: Richard Graham and Aziz Sawaf

​

•

For 2022: Andrew Hindman, Rhonda Farnum, Richard Graham and Ann Brady

​

(4)

The dollar amounts reported in this column represent the average of the amounts reported for the non-PEO NEOs in the “Total” column of the Summary Compensation Table in the applicable fiscal year.

​

(5)

In accordance with SEC rules, the following adjustments were made to determine the compensation actually paid on average to our non-PEO NEOs during fiscal years 2024, 2023 and 2022, which consisted solely of adjustments to the non-PEO NEOs’ equity awards:

​

| Description of Adjustment                                                                                                                                                                 | ​ | ​ | 2024 |   |           |   | ​ | ​ | 2023 |   |           |   | ​ | ​ | 2022 |   |          |   | ​ |
|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:--|:--|:-----|:--|----------:|:--|:--|:--|:-----|:--|----------:|:--|:--|:--|:-----|:--|---------:|:--|:--|
| Summary Compensation Table – Total Compensation                                                                                                                                           | ​ | ​ | ​    | $ | 1,466,136 | ​ | ​ | ​ | ​    | $ | 1,396,517 | ​ | ​ | ​ | ​    | $ |  971,395 | ​ | ​ |
| - grant date fair value of option awards and stock awards granted inthe covered fiscal year                                                                                               | ​ | ​ | ​    | $ |  -790,624 | ​ | ​ | ​ | ​    | $ |  -778,100 | ​ | ​ | ​ | ​    | ​ |        — | ​ | ​ |
| + fair value at fiscal